At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 20 enrolled
Drug / intervention
OPB-51602drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
In the news
3 articles- Antag Therapeutics presents positive Phase 1 results at the 2026 Scientific Sessions of the American Diabetes Association for AT7687, a first-in-class GIPR antagonistGlobeNewswire Biotech·2026-06-07press release
- Shattuck Labs to Host Investor Call and Webcast on Phase 1 Clinical Data of SL-325, a Potentially First-in-Class DR3 Blocking Antibody, and Pipeline Update on June 8GlobeNewswire Biotech·2026-06-05press release
- Climb Bio Presents CLYM116 Initial Phase 1 Safety Data and Translational Modeling Results at European Renal Association (ERA) Congress 2026 Supporting Continued DevelopmentGlobeNewswire Biotech·2026-06-05press release
Matched to this trial by ClinicalIndexfrom reputable biotech & medical press.
A Dose-escalation Trial to Investigate the Safety and Tolerability of OPB-51602 in Patients With Relapsed or Refractory Hematologic Malignancies (Phase 1)
In Brief
A Phase 1 clinical trial evaluating OPB-51602 for Multiple Myeloma and 4 related conditions. Completed, enrolled 20 participants across 2 sites.
Detailed Summary
To determine the maximum tolerated dose (MTD) of OPB-51602
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMultiple Myeloma, Non-Hodgkin Lymphoma, Acute Myeloid Leukemia, Acute Lymphoid Leukemia, Chronic Myeloid Leukemia
CountriesJapan
Collaborators--
Timeline
Phase 1CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
Enrollment StartApr 2011
First PostedApr 2011
Primary CompletionApr 2014
TodayJul 2026
First PostedApr 29, 2011
Enrollment StartApr 1, 2011
Primary CompletionApr 1, 2014
TodayJul 2, 2026
Enrollment to primary: 3 yearsPosted 15.2 years ago
Interventions
OPB-51602drug
once daily during the treatment period